Posted by Michael Wonder on 28 Jan 2022
Highlights from CHMP 24-27 January 2022 meeting
28 January 2022 - EMA’s CHMP recommended seven medicines for approval at its January 2022 meeting.
The CHMP gave a positive opinion for the new gene therapy Breyanzi (lisocabtagene maraleucel) for the treatment of relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma grade 3B after at least two previous lines of treatment.
